• InMed Pharmaceuticals completed a 1-for-10 common share consolidation on November 4, 2026.
• Outstanding common shares fell from 5,493,735 to approximately 549,374.
• Post-consolidation trading is expected to begin November 5, 2026, on the Nasdaq Capital Market under the existing symbol INM.
• The company also changed its name to Mentari Therapeutics, effective November 4, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611041651NEWSFILECNPR____20261104_322587_1) on November 04, 2026, and is solely responsible for the information contained therein.